FDA Brief

Warning letters Drugs

FDA warning letter to

Eli Lilly and Company

LowIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA says Eli Lilly's sponsored Zepbound video omitted risk and use information, misbranding the drug.

What happened

FDA reviewed a sponsored direct-to-consumer online video interview featuring Eli Lilly representatives, posted on okcfox.com and originally appearing July 11, 2025. FDA determined the video was false or misleading because it promoted Zepbound without communicating any risk information and omitted the drug's limitations of use. FDA also said the video was not submitted under Form FDA-2253 at initial publication.

What FDA found

  1. The video promoted Zepbound without any risk information despite serious risks including a boxed warning for thyroid C-cell tumors.

    21 U.S.C. 352(a), (n); 321(n); 331(a); 21 CFR 202.1(e)(5)
  2. The video omitted Zepbound's limitations of use, including that it is not recommended with other tirzepatide products or GLP-1 receptor agonists.

    21 U.S.C. 352(a), (n); 321(n); 331(a); 21 CFR 202.1(e)(3)(i)
  3. Eli Lilly did not submit the video to FDA under Form FDA-2253 at the time of initial publication.

    21 CFR 314.81(b)(3)(i)

What FDA wants

FDA asks Eli Lilly to stop the misleading communications immediately and submit a written response within 15 working days, listing other similar Zepbound communications and a plan to discontinue them or cease distribution. FDA also requests a plan for corrective communications to the audience that received the video.

Who should pay attention

  • drug advertising and promotional review teams
  • pharmaceutical companies that use sponsored videos or social media
  • telehealth and pharmacy platforms that host manufacturer-sponsored content

This is a summary. Read the original letter on fda.gov.

Eli Lilly and Company's FDA history

  1. Eli Lilly and Company

    FDA says Eli Lilly’s Oprah-linked video for Zepbound and Mounjaro misled on serious risks.

    High risk
  2. Eli Lilly and Company

    FDA says Eli Lilly's Zepbound online video omitted risk and limitations information and was not submitted to FDA.

    High risk

Full company page

Similar letters to other companies

  1. Amgen Inc.

    FDA says an Amgen promotional video for the cancer drug Vectibix is false and misleading because it leaves out all risk information.

    Medium
  2. Stokes Healthcare Inc. dba Epicur Pharma

    FDA warned Epicur Pharma over website claims for compounded omeprazole and buprenorphine animal drugs that are false or misleading.

    High risk
  3. Herbal Dermals LLC FZ dba Gotucream

    FDA warned Herbal Dermals LLC FZ dba Gotucream that its Gotucream balanitis cream is an unapproved new drug.

    Low
  4. Nexus Health Solutions LLC dba Harper Meds

    FDA warned telehealth seller Harper Meds that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Low